ML-239

Confirm delete?

ML-239

Zoom

Cat No: 15188

Biochemicals - More Biochemicals

ML-239 is an inhibitor of cancer stem cells, displaying greater than 23-fold selective inhibition of a breast cancer stem cell-like cell line (EC50 = 1.18 µM) over an isogenic control cell line (EC50 = 27.6 µM).{24522,24523,24524} It is also toxic to ...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

2-(2,4,6-trichlorophenoxy)-acetic acid, (2E)-2-(1H-pyrrol-2-ylmethylene)hydrazide

Correlated keywords:

inhibitors cancers genes regulations stems cells researchs inhibits inhibitions breasts ML239 MLs 239 selective cell-like like lines toxic carcinomas MDA-MB-231 MDAMB231 MDA MB 231 genes saline glutathione humans plasmas CIDs CID-49843203 CID49843203 ML-239 23-fold 23 folds isogenic controls expressions MAPK NF-kB NK-kappaB NF-.kappa.B NFs kB ?B NF-?B kappaB .kappa.B inflammatory cytokines pathways stable CID-49843203 CID49843203 CID 49843203

Product Overview:
ML-239 is an inhibitor of cancer stem cells, displaying greater than 23-fold selective inhibition of a breast cancer stem cell-like cell line (EC50 = 1.18 µM) over an isogenic control cell line (EC50 = 27.6 µM).{24522,24523,24524} It is also toxic to the breast carcinoma cell line MDA-MB-231.{24522} ML-239 alters the expression of genes in the MAPK, NF-κB, and inflammatory cytokine pathways.{24522,24524} It is stable in saline and modestly stable in human plasma.{24523}

Size	1 mg
Shipping	dry ice
CAS Number	1378872-36-6
Molecular Formula	C₁₃H₁₀Cl₃N₃O₂
SMILES	O=C(COC1=C(Cl)C=C(Cl)C=C1Cl)N/N=C/C2=CC=CN2
Molecular Weight	346,6
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2903.99
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.